Literature DB >> 28053319

Pre-diagnostic genotyping identifies T1D subjects with impaired Treg IL-2 signaling and an elevated proportion of FOXP3+IL-17+ cells.

A K Marwaha1, C Panagiotopoulos2, C M Biggs1, S Staiger1, K L Del Bel3, A F Hirschfeld3, J J Priatel1, S E Turvey3, R Tan1,4,5.   

Abstract

T-regulatory cells (Tregs) are essential for immune tolerance, and animal studies implicate their dysfunction in type 1 diabetes (T1D) pathogenesis. Tregs require interleukin-2 (IL-2) for their suppressive function, and variants in IL-2/IL-2R pathway genes have been associated with T1D. We previously reported that recent-onset T1D subjects have an increased population of FOXP3lo Tregs that secrete the pro-inflammatory cytokine, interleukin-17 (IL-17). We hypothesize that IL-2 signaling defects may drive T1D development by skewing protective Tregs towards an inflammatory Th17 phenotype. Overall, we found that the proportion of FOXP3+IL-17+ cells in T1D subjects pre-diagnosis was unchanged compared with healthy controls. However, stratification by IL2RA single-nucleotide polymorphisms revealed that T1D subjects with the rs3118470 CC risk variant have Tregs with IL-2 signaling defects and an increased proportion of FOXP3+IL-17+ cells before diagnosis. These data suggest a potential mechanism for genetically controlled loss of Treg function via dysfunctional IL-2 signaling in T1D.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28053319      PMCID: PMC5843473          DOI: 10.1038/gene.2016.44

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  24 in total

1.  The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Authors:  Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler
Journal:  Pediatr Diabetes       Date:  2008-09-24       Impact factor: 4.866

2.  Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource.

Authors:  Calliope A Dendrou; Vincent Plagnol; Erik Fung; Jennie H M Yang; Kate Downes; Jason D Cooper; Sarah Nutland; Gillian Coleman; Matthew Himsworth; Matthew Hardy; Oliver Burren; Barry Healy; Neil M Walker; Kerstin Koch; Willem H Ouwehand; John R Bradley; Nicholas J Wareham; John A Todd; Linda S Wicker
Journal:  Nat Genet       Date:  2009-08-23       Impact factor: 38.330

Review 3.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Authors:  Wei Liao; Jian-Xin Lin; Warren J Leonard
Journal:  Immunity       Date:  2013-01-24       Impact factor: 31.745

4.  Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of type 1 diabetes in the Japanese population.

Authors:  Eiji Kawasaki; Takuya Awata; Hiroshi Ikegami; Tetsuro Kobayashi; Taro Maruyama; Koji Nakanishi; Akira Shimada; Miho Uga; Susumu Kurihara; Yumiko Kawabata; Shoichiro Tanaka; Yasuhiko Kanazawa; Katsumi Eguchi
Journal:  J Clin Endocrinol Metab       Date:  2008-12-23       Impact factor: 5.958

5.  A cis-acting regulatory variant in the IL2RA locus.

Authors:  Hui-Qi Qu; Dominique J Verlaan; Bing Ge; Yang Lu; Kevin C L Lam; Rosemarie Grabs; Eef Harmsen; Thomas J Hudson; Hakon Hakonarson; Tomi Pastinen; Constantin Polychronakos
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

6.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Authors:  Agnès Hartemann; Gilbert Bensimon; Christine A Payan; Sophie Jacqueminet; Olivier Bourron; Nathalie Nicolas; Michèle Fonfrede; Michelle Rosenzwajg; Claude Bernard; David Klatzmann
Journal:  Lancet Diabetes Endocrinol       Date:  2013-10-08       Impact factor: 32.069

Review 7.  The functional plasticity of T cell subsets.

Authors:  Jeffrey A Bluestone; Charles R Mackay; John J O'Shea; Brigitta Stockinger
Journal:  Nat Rev Immunol       Date:  2009-10-07       Impact factor: 53.106

8.  Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

Authors:  Christopher E Lowe; Jason D Cooper; Todd Brusko; Neil M Walker; Deborah J Smyth; Rebecca Bailey; Kirsi Bourget; Vincent Plagnol; Sarah Field; Mark Atkinson; David G Clayton; Linda S Wicker; John A Todd
Journal:  Nat Genet       Date:  2007-08-05       Impact factor: 38.330

9.  IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.

Authors:  Lisa M Maier; Christopher E Lowe; Jason Cooper; Kate Downes; David E Anderson; Christopher Severson; Pamela M Clark; Brian Healy; Neil Walker; Cristin Aubin; Jorge R Oksenberg; Stephen L Hauser; Alistair Compston; Stephen Sawcer; Philip L De Jager; Linda S Wicker; John A Todd; David A Hafler
Journal:  PLoS Genet       Date:  2009-01-02       Impact factor: 5.917

10.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

View more
  11 in total

1.  Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Authors:  Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko
Journal:  Diabetes       Date:  2019-07       Impact factor: 9.461

Review 2.  Genetic and epigenetic influences on the loss of tolerance in autoimmunity.

Authors:  Peng Zhang; Qianjin Lu
Journal:  Cell Mol Immunol       Date:  2018-03-05       Impact factor: 11.530

3.  Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.

Authors:  Katharine Schwedhelm; Jerill Thorpe; Sara A Murray; Marc Gavin; Cate Speake; Carla Greenbaum; Karen Cerosaletti; Jane Buckner; S Alice Long
Journal:  Clin Immunol       Date:  2017-06-20       Impact factor: 3.969

4.  Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Authors:  Carla J Greenbaum; Cate Speake; Jeffrey Krischer; Jane Buckner; Peter A Gottlieb; Desmond A Schatz; Kevan C Herold; Mark A Atkinson
Journal:  Diabetes       Date:  2018-05-16       Impact factor: 9.461

Review 5.  Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes.

Authors:  Maria Bettini; Matthew L Bettini
Journal:  Diabetes       Date:  2021-05-20       Impact factor: 9.337

Review 6.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 7.  Cell death pathologies: targeting death pathways and the immune system for cancer therapy.

Authors:  Francesca Pentimalli; Sandro Grelli; Nicola Di Daniele; Gerry Melino; Ivano Amelio
Journal:  Genes Immun       Date:  2018-12-19       Impact factor: 2.676

8.  Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes.

Authors:  Robert Z Harms; Kristina M Lorenzo-Arteaga; Katie R Ostlund; Victoria B Smith; Lynette M Smith; Peter Gottlieb; Nora Sarvetnick
Journal:  Front Immunol       Date:  2018-10-22       Impact factor: 7.561

9.  Clinical Applications of Regulatory T cells in Adoptive Cell Therapies.

Authors:  Gregory P Marshall; Judit Cserny; Daniel J Perry; Wen-I Yeh; Howard R Seay; Ahmed G Elsayed; Amanda L Posgai; Todd M Brusko
Journal:  Cell Gene Ther Insights       Date:  2018-01

Review 10.  Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Authors:  Carolina Lavoz; Sandra Rayego-Mateos; Macarena Orejudo; Lucas Opazo-Ríos; Vanessa Marchant; Laura Marquez-Exposito; Antonio Tejera-Muñoz; Juan F Navarro-González; Alejandra Droguett; Alberto Ortiz; Jesús Egido; Sergio Mezzano; Raúl R Rodrigues-Diez; Marta Ruiz-Ortega
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.